RxDoctor Payments Data

David Cykert

Internal Medicine · Spartanburg, SCNPI 1154777456

Payments from drug & device makers

$8,725in general payments, 2019–2025

Across 530 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$826
  • AstraZeneca$503
  • Astellas Pharma US Inc$454
  • Amgen$441
  • Novo Nordisk$424
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$8,53898%
  • Education$1872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie120$1,605
Pfizer53$826
AstraZeneca32$503
Astellas Pharma US Inc17$454
Amgen33$441
Novo Nordisk31$424
Novartis18$328
Exact Sciences12$316
GSK18$272
Takeda Pharmaceuticals U.S.A., Inc.15$256
Sumitomo Pharma America, Inc.12$244
Lilly USA, LLC15$228
Dexcom, Inc.13$216
Abbott8$167
Amarin Pharma, Inc.11$161
Boehringer Ingelheim9$151
Inari Medical, Inc.4$139
Bayer9$136
Daiichi Sankyo Inc.6$131
Esperion Therapeutics, Inc.6$118
Neurocrine Biosciences, Inc.6$115
Kowa Pharmaceuticals America, Inc.8$105
Verona Pharma, Inc.5$98
Eisai Inc.5$89
Otsuka America Pharmaceutical, Inc.4$77
Stryker1$73
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$65
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$64
Axsome Therapeutics, Inc.3$59
Biohaven Pharmaceutical Holding Company Ltd.3$56
Lundbeck LLC3$53
Sanofi-aventis U.S. LLC3$48
Shield Therapeutics Inc3$48
Corium, LLC3$47
Merck3$45
Medtronic2$44
Halozyme Inc2$42
Phathom Pharmaceuticals, Inc.2$36
Antares Pharma, Inc.2$34
Tolmar, Inc.2$34
Genentech USA, Inc.2$31
ANI Pharmaceuticals, Inc.1$31
Edwards Lifesciences1$28
Idorsia Pharmaceuticals US Inc2$27
Vifor Pharma, Inc.1$26
Recor Medical Inc1$25
Biohaven Pharmaceuticals, Inc.1$22
Inspire Medical Systems, Inc.1$20
Xeris Pharmaceuticals, Inc.1$19
Philips North America LLC1$17
Boston Scientific1$17
Ironwood Pharmaceuticals, Inc1$17
Acadia Pharmaceuticals Inc1$17
Dynavax Technologies Corporation1$16
Upsher-smith Laboratories LLC1$14
Tonix Medicines, Inc.1$14
Teva Pharmaceuticals USA, Inc.1$13
IBSA Pharma Inc.1$12
Johnson & Johnson1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,725 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$160,820
Medicare patients
408
Services billed
3,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban237$196,455
OzempicSemaglutide82$109,267
MounjaroTirzepatide77$91,350
FarxigaDapagliflozin Propanediol83$66,581
XareltoRivaroxaban70$54,026
JardianceEmpagliflozin47$49,243
JanuviaSitagliptin Phosphate50$49,220
MyrbetriqMirabegron40$35,021
RybelsusSemaglutide23$33,916
Breo ElliptaFluticasone/Vilanterol77$32,504
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$32,294
Repatha SureclickEvolocumab40$28,614
LinzessLinaclotide25$25,858
TrulicityDulaglutide17$23,027
EntrestoSacubitril/Valsartan11$21,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$826$196,455237 claims
Novo NordiskOzempic, Rybelsus$424$143,183105 claims
Lilly USA, LLCMounjaro, Trulicity$228$114,37794 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$503$83,488118 claims
MerckJanuvia, Janumet, Janumet Xr$45$68,80681 claims
GSKBreo Ellipta, Trelegy Ellipta$272$64,799124 claims
Johnson & JohnsonXarelto$12$54,02670 claims
Boehringer IngelheimJardiance$151$49,24347 claims
Astellas Pharma US IncMyrbetriq$454$35,02140 claims
AbbVieLinzess, Lexapro$1,605$30,63036 claims
NovartisEntresto$328$21,81011 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$256$15,11531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →